Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Krebs cycle reborn in macrophage immunometabolism
November 2022
Introduction A marked rise in the global prevalence of obesity and associated metabolic pathologies has been observed over the past 30 years ( Globally, more than 1 billion people are estimated to have NAFLD, including 83 million patients in the United States, making NAFLD the most common chronic liver disease in the US ( NASH is diagnosed histologically, based on the extent of steatosis, hepatocyte stress and damage (hepatocyte ballooning), immune infiltration (lobular inflammation), and degree of fibrosis ( While late-stage NASH greatly increases the risk of liver-related morbidity, NAFLD and NASH with less advanced fibrosis (i.e., F0F2) are associated with greatly increased risk of cardiovascular disease and related mortality ( Despite the unmet medical need, there is currently no approved therapy for NASH
Those with suspected fatty liver: The liver-supporting MIC combination may help improve hepatic function
